GeneReach Biotechnology Valuation
| 4171 Stock | TWD 27.25 1.10 3.88% |
At this time, the firm appears to be fairly valued. GeneReach Biotechnology retains a regular Real Value of NT$27.82 per share. The prevalent price of the firm is NT$27.25. Our model calculates the value of GeneReach Biotechnology from evaluating the firm fundamentals such as Return On Equity of 0.3, return on asset of 0.13, and Current Valuation of 2.09 B as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that GeneReach Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of GeneReach Biotechnology is based on 3 months time horizon. Increasing GeneReach Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GeneReach stock is determined by what a typical buyer is willing to pay for full or partial control of GeneReach Biotechnology. Since GeneReach Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GeneReach Stock. However, GeneReach Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.25 | Real 27.82 | Hype 28.35 | Naive 28.84 |
The intrinsic value of GeneReach Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GeneReach Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GeneReach Biotechnology helps investors to forecast how GeneReach stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GeneReach Biotechnology more accurately as focusing exclusively on GeneReach Biotechnology's fundamentals will not take into account other important factors: GeneReach Biotechnology Total Value Analysis
GeneReach Biotechnology is presently anticipated to have takeover price of 2.09 B with market capitalization of 2.73 B, debt of 217.39 M, and cash on hands of 811.4 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GeneReach Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.09 B | 2.73 B | 217.39 M | 811.4 M |
GeneReach Biotechnology Investor Information
About 35.0% of the company shares are owned by insiders or employees . The book value of GeneReach Biotechnology was presently reported as 24.36. The company recorded earning per share (EPS) of 6.9. GeneReach Biotechnology last dividend was issued on the 13th of September 2022. The entity had 1000:1250 split on the 24th of July 2023. Based on the key measurements obtained from GeneReach Biotechnology's financial statements, GeneReach Biotechnology is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.GeneReach Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GeneReach Biotechnology has an asset utilization ratio of 60.08 percent. This indicates that the Company is making NT$0.6 for each dollar of assets. An increasing asset utilization means that GeneReach Biotechnology is more efficient with each dollar of assets it utilizes for everyday operations.GeneReach Biotechnology Ownership Allocation
GeneReach Biotechnology has a total of 45.97 Million outstanding shares. GeneReach Biotechnology secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GeneReach Biotechnology Profitability Analysis
The company reported the revenue of 1.01 B. Net Income was 376.62 M with profit before overhead, payroll, taxes, and interest of 746.98 M.About GeneReach Biotechnology Valuation
Our relative valuation model uses a comparative analysis of GeneReach Biotechnology. We calculate exposure to GeneReach Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GeneReach Biotechnology's related companies.GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
8 Steps to conduct GeneReach Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GeneReach Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GeneReach Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain GeneReach Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GeneReach Biotechnology's revenue streams: Identify GeneReach Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GeneReach Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish GeneReach Biotechnology's growth potential: Evaluate GeneReach Biotechnology's management, business model, and growth potential.
- Determine GeneReach Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GeneReach Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.